PRESS RELEASES AND NEWS
August 15, 2023
SiVEC's CEO, Lyndsey Linke, was recently featured on the Integrate & Ignite Marketing Podcast
Host Lori Jones and Lyndsey dive into her journey of co-founding SiVEC, a game-changing biotech company with a groundbreaking drug delivery platform, and how the team is making waves in the industry as a top emerging company. The interview also talks about the incredible ecosystem supporting technology development in Colorado! Join us for this exciting conversation about commercializing science, acquiring business acumen, and embracing a risk-taking mindset.
May 23, 2023
SiVEC’s CEO and co-founder, Dr. Lyndsey Linke, has been appointed as a new board member for the Colorado BioScience Association
As a visionary health innovator who is passionate about building and growing successful life sciences companies in Colorado, Lyndsey is honored to be recognized as a respected leader in the life science’s community. She looks forward to beginning this new endeavor where she will work closely with CBSA, CBSA members, and Colorado’s life science community as they continue to gain momentum and advance Colorado’s life science ecosystem to the top 5!
May 18, 2023
SiVEC Biotechnologies awarded grant from the Colorado Office of Economic Development and International Trade
Our exceptional team at SiVEC Biotechnologies has reached yet another milestone! The grant awarded by the Colorado Office of Economic Development and International Trade is a testament to SiVEC’s hard work and dedication to their mission of advancing nucleic acid and gene therapies with a focus on safe and precise tissue-targeted delivery. This $250,000 grant will enable SiVEC to advance a first-in-class cancer therapeutic targeting oncogenic-KRAS into IND-enabling stages.
April 27, 2023
SiVEC Biotechnologies wins first prize in the Innovator's Pitch Challenge Digital RESI March
The Innovator’s Pitch Challenge allows early-stage companies to gain additional exposure to conference attendees and pitch directly to a panel of active investors and industry experts.
The March event, a perennial highlight of RESI, featured more than 34 competing companies. Among the presenters, Dr. Lyndsey Linke (SiVEC CEO) was awarded the first place prize.
February 5, 2023
SiVEC Biotechnologies publishes paper on the safety and efficacy of its live bacterial delivery vehicle
The new publication, published on February 5, 2023, appears in the journal Engineering in Life Sciences.
SiVEC is pleased to announce the publication of our groundbreaking scientific paper entitled "An optimized live bacterial delivery vehicle safely and efficaciously delivers bacterially transcribed therapeutic nucleic acids" in the journal Engineering in Life Sciences on February 5, 2023. The paper describes a new delivery platform that addresses the limitations of current nucleic acid delivery systems, including poor targeting specificity, inefficient access to target cell cytoplasm, immune activation, off-target effects, small therapeutic windows, limited genetic encoding and cargo capacity, and manufacturing challenges. The new platform comprises engineered live, tissue-targeting, non-pathogenic bacteria that specifically bind to epithelial cells via a surface-expressed targeting ligand, allow escape of their cargo from the phagosome, and have minimal immunogenicity. The paper reports the platform's ability to deliver short hairpin RNA (shRNA) to various tissues and describes its minimal immunogenicity. The authors validated the platform's therapeutic potential by using it to deliver influenza-targeting antiviral shRNAs to respiratory tissues in vivo, establishing its safety and efficacy for use in multiple tissue types and as an antiviral in the mammalian respiratory tract. This optimized delivery platform is expected to enable a variety of advanced therapeutic approaches.
September 14, 2022
SiVEC Biotechnologies recognized as the 2022 Top Emerging Start-Up Company by BIO International
SiVEC's CEO Lyndsey Linke participated in the BIO International Start-Up Stadium, a competition featuring live pitches from 42 finalist companies.
“This year’s BIO Start-Up Stadium had record-setting participation from the number of start-up applicants, number of start-up’s pitching, number of judges, and sizes of audiences attending since the program launched in 2015,” said Bernard V. Fallon, BIO’s Managing Director of Industry Research, Investor Outreach, and Education.
SiVEC Biotechnologies scored the highest among the emerging start-up companies, in a competition featuring live pitches from 42 finalist competitors.
September 23, 2021
SiVEC Biotechnologies receives funding from NIH/NCATS to develop its delivery platform for gene editing machinery
This funding represents SiVEC's second phase I SBIR award, highlighting the value appreciated by the NIH and expert review panels.
The therapeutic potential of gene editing is limited by several shortcomings of current delivery platforms (e.g., viruses, mechanical, and non-viral), including weak targeting to specific cells or tissues, limited cargo size, difficulties in cellular entry, immune activation, off-target events, and manufacturing challenges. In this project, SiVEC will engineer its core delivery platform, which consists of invasive, tissue-targetable, non-immunogenic bacteria, for in vivo delivery of CRISPR/Cas gene editing components. Successful leveraging of SiVEC’s previously validated delivery platform will overcome these key limitations, thereby providing a new tool in the quest to realize the full potential of gene editing in the treatment of human disease.
September 23, 2021
SiVEC Biotechnologies selected to participate in the 2021 NIH Innovation Conference and Life Science Summit
SiVEC has been selected as an emerging biotech company to participate in the 2021 NIH Innovation Conference (Monday, October 4th), and Life Science Summit (LSS - a two-day virtual event Tuesday, November 9th and Wednesday, November 10th). The two-day LSS program features corporate presentations by promising young companies with transformative science that targets unmet medical needs. It will also feature informative plenary sessions, business workshops, and therapeutic sessions. The opportunity to present at these two prestigious events is a great recognition and tribute to the innovative work behind SiVEC.
September 23, 2021
Osage University Partners features CEO Lyndsey Linke as an inspiring female founder
As part of their celebration of National Women's Small Business Month this October, the VC firm OUP interviewed Lyndsey to discuss her journey as a female founder. Their goal was "to showcase real-life examples of women in academia and industry with the hope that hearing these journeys from bench to entrepreneur will provide inspiration and guidance to more potential entrepreneurs". Visit the link below to read her interview.
March 23, 2021
SiVEC Biotechnologies wins pitch competition at Amgen-CBSA Healthcare innovation event
SiVEC CEO Dr. Lyndsey Linke competed in and won the pitch competition at the Amgen-CBSA Healthcare Innovation event held March 23, 2021. SiVEC received a grant from Amgen as well as mentoring from Amgen experts. This event, sponsored by Amgen in partnership with Colorado BioScience Association, was held to bring together various members of Colorado's life sciences and healthcare ecosystem.